Anti-CD22-MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination

Bioconjugate Chemistry

Volumn 19, Issue 8, 2008, Pages 1673-1683

  Stephan, Jean Philippe ^a   Chan, Pamela ^a   Lee, Chien ^a   Nelson, Christopher ^a   Elliott, James Michael ^a   Bechtel, Charity ^a   Raab, Helga ^a   Xie, David ^a   Akutagawa, Jon ^a   Baudys, Jakub ^a   Saad, Ola ^a   Prabhu, Saileta ^a   Wong, Wai Lee T ^a   Vandlen, Richard ^a   Jacobson, Fred ^a   Ebens, Allen ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHARMACOKINETICS;

ANTIBODY ASSAYS; ANTIBODY-DRUG CONJUGATES; B CELLS; DRUG LOAD; MULTIPLE ASSAYS; PARAMETER DETERMINATION; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC PROFILES;

ANTIBODIES;

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; CD22 MONOCLONAL ANTIBODY MONOMETHYL AURISTATIN F CONJUGATE; CD22 MONOCLONAL ANTIBODY MYTANSINOID CONJUGATE; SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; SULFIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; MOUSE; NONHUMAN; SINGLE DRUG DOSE;

EID: 50249161528     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800059t     Document Type: Article

References (27)

1. Garnett, M. C. (2001) Targeted drug conjugates: principles and progress. Adv. Drug Delivery Rev. 53, 171-216.
2. Lambert, J. M. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5, 543-549.
3. Polakis, P. (2005) Arming antibodies for cancer therapy. Curr. Opin. Pharmacol. 5, 382-387.
4. Sanderson, R. J., Hering, M., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linker auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852.
5. Xie, H., Audette, C., Hoffee, M., Lambert, J. M., and Blatter, W. A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and it two components in mice. J. Pharmacol. Exp. Ther. 308, 1073-1082.
6. Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blatter, W. A., and Goldmacher, V. S. (2006) Antibody-drug conjugates designed to eradicate tumor with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214-3221.
7. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hellet, W., Tsou, H. R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-clicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 13, 47-58.
8. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784.
9. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 17, 114-124.
10. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blättler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433.
11. Nitschke, L., Floyd, H., and Croker, P. R. (2001) New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs. Scand. J. Immunol. 53, 227-234.
12. Crocker, P. R., and Varki, A. (2001) Siglecs in the immune system. Immunology 103, 137-145.
13. Crocker, P. R., and Varki, A. (2001) Siglecs, sialic acids and innate immunity. Trends Immunol. 22, 337-342.
14. Hursey, M., Newton, D. L., Hansen, H. J., Ruby, D., Goldenberg, D. M., and Rybak, S. M. (2002) Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk. Lymphoma 43, 953-959.
15. Moyron-Quiroz, J. E., Partida-Sanchez, S., Donis-Hernandez, R., Sandoval-Montes, C., and Santos-Argumedo, L. (2002) Expression and function of CD22, a B-cell restricted molecule. Scand. J. Immunol. 55, 343-351.
16. Tedder, T. F., Tuscano, J., Sato, S., and Kehrl, J. H. (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 15, 481-504.
17. Kreitman, R. J. (2001) Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2, 313-325.
18. Pastan, I., and Kreitman, R. J. (2002) Immunotoxins in cancer therapy. Curr. Opin. Invest. Drugs 3, 1089-1091.
19. Kreitman, R. J. (2003) Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5, 44-51.
20. Chart, R. V. J., Martell, B. A., Gross, J. L., Cook, S. B., Shah, S. A., Blättler, W. A., McKenzie, S. J., and Goldmacher, V. S. (1992) Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 52, 127-131.
21. Liu, C., and Chart, R. V. J. (1997) The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin. Invest. Drugs 6, 169-172.
22. McDonagh, C. F., Turcott, E., Westerndorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francsco, J. A., and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometrics of drug attachment. Protein Eng. Des. Selection 19, 299-307.
23. Foote, J., and Winter, G. (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224, 487-499.
24. Hongo, J. A., Mora-Worms, M., Lucas, C., and Fendly, B. M. (1995) Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor beta 1. Hybridoma 14, 253-260.
25. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323-327.
26. Polson, A. G., Yu, S. F., Elkins, K., Zheng, B., Clark, S., Ingle, G. S., Slaga, D. S., Giere, L., Du, C., Tan, C., Hongo, J. A., Gogineni, A., Cole, M. J., Vandlen, R., Stephan, J. P., Young, J., Chang, W., Scales, S. J., Ross, S., Eaton, D., and Ebens, A. (2007) Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood 110, 616-623.
27. Hambblett, K. J., Senter, P. D., Chace, D., F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effect of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070.